FemtoVox Incorporated is proud to announce that it has successfully raised $4,500,000 in its latest funding round—a milestone that marks a significant step forward in the evolution of surgical technology. Founded on the vision that surgery need not be a painful ordeal fraught with complications, FemtoVox is reinventing the operating room with cutting-edge innovations that promise unparalleled precision and dramatically reduced tissue damage. This groundbreaking infusion of capital will accelerate the company’s mission to transition from traditional, imprecise surgical techniques to an era defined by fiber delivery for endoscopic surgery, advanced robotic integration, and revolutionary line-of-sight capabilities.
With its technology delivering thousandth-of-an-inch precision and surgically precise tissue ablation that preserves the surface while targeting underlying layers, FemtoVox is setting a new benchmark in surgical care. The company’s current focus is particularly compelling for the hundreds of thousands of Americans—and millions worldwide—suffering from chronic vocal dysfunction. In these cases, traditional interventions may irrevocably alter a patient’s voice; however, FemtoVox’s innovative approach offers a solution that minimizes soft tissue damage, promising hope to those previously faced with limited options.
Led by pioneers who were instrumental in developing the world’s first femtosecond laser surgical devices, accounting for over 10 million surgeries globally, FemtoVox benefits from a strong foundation of expertise and trusted investor partnerships, including First Spark Ventures, Mayo Clinic Ventures, and C3 Ventures. This latest funding achievement not only validates the company’s disruptive technology but also fuels its drive to redefine surgical precision and improve patient outcomes worldwide.
